Citations

Showing 10 of 108094 citations.

International Consensus Statement on Obstructive Sleep Apnea
Chang, Jolie L. , Goldberg, Andrew N. , Alzoubaidi, Mohammed , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bakhtiar, H., Bartley, Bethany L. , Billings, Martha E. , Boon, Maurits , Bosschieter, Pien F. N. , Braverman, Itzhak , Brodie, Kara D. , Caesar, Ray, Cahali, Michel Burihan, Cai, Yi , Cao, Michelle , Capasso, Robson , Caples, Sean M., Chang, Corissa P. , Chang, Katherine W. , Chaudhary, Nilika, Cheong, Crystal , Chowdhuri, Susmita , Cistulli, Peter A. , Claman, David M., Collen, Jacob , Coughlin, Kevin , Creamer, Jennifer , Davis, Eric M. , Dupuy-McCauley, Kara , Durr, Megan L. , Dutt, Mohan, Ali, Mazen El, Elkassabany, Nabil , Epstein, Lawrence J., Fiala, Justin A. , Freedman, Neil, Gill, Kirat, Gillespie, M. Boyd , Golisch, Lea, Gooneratne, Nalaka S., Gottlieb, Daniel J. , Green, Katherine K., Gurubhagavatula, Indira , Hayward, Nathan, Hoffmann, Oliver M. G., Holfinger, Steven , Hsia, Jennifer, Huoh, Kevin C. , Inala, Sanjana , Jobanputra, Aesha M. , Johnson, Andrew P. , Junna, Mithri R. , Kado, Jenna T. , Kaffenberger, Thomas M. , Khan, Meena , Kirsch, Douglas B. , Kominsky, Alan, Kryger, Meir H. , Kushida, Clete A. , Kuzniar, Thomas J., Lim, Diane C , Liu, Stanley Yung‐Chuan , MacKay, Stuart G. , Maurer, Joachim T. , May, Anna M. , Mitchell, Ron B. , Mullins, Anna , Nada, Eman , Naik, Sreelatha , Nokes, Brandon , Olson, Michael D. , Pang, Edward B. , Pang, Kenny P. , Perck, Eli Van de , Piccirillo, Jay F. , Pien, Grace W. , Plawecki, Andrea , Quigg, Mark , Ravesloot, Madeline J. L. , Redline, Susan , Rotenberg, Brian , Ryden, Armand, Sarmiento, Kathleen , Sbeih, Firas , Schell, Amy E., Schotland, Helena , Schwab, Richard J. , Seo, Jiyeon , Shah, Neomi , Shelgikar, Anita V., Shochat, Isaac , Soose, Ryan J. , Steele, Toby O. , Stephens, Erika M. , Stepnowsky, Carl , Thaler, Erica R. , Thapa, Sritika, Vries, Nico de, Weaver, Edward M. , Weir, Ian, Wolfe, Lisa F. , Woodson, B. Tucker , Won, Christine , Xu, Josie , Yalamanchi, Pratyusha , Yaremchuk, Kathleen , Yeghiazarians, Yerem, Yu, Jason L. , Zeidler, Michelle , Rosen, Ilene M. , Alt, Jeremiah A , Mohammed, Alzoubaidi , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bartley, Bethany L , Braverman, Itzhak , Cahali, Michel B , Cai, Yi , Cheong, Crystal S J , Chowdhuri, Susmita , Cistulli, Peter A , Creamer, Jennifer , Dupuy-McCauley, Kara L , Durr, Megan L , Elkassabany, Nabil M , Fiala, Justin A , Gottlieb, Daniel J , Gulati, Arushi , Holfinger, Steven J , Huntley, Colin , Huyett, Phillip , Inala, Sanjana , Ishman, Stacey L , Jobanputra, Aesha M , Kado, Jenna T , Kezirian, Eric J , Kirsch, Douglas B , Kushida, Clete A , Lam, Derek J , Lettieri, Christopher J , Lin, Hsin-Ching , Magalang, Ulysses J , Malhotra, Atul , Mansukhani, Meghna P , Maurer, Joachim T , May, Anna M , Mitchell, Ron B , Mullins, Anna E , Nada, Eman M , Naik, Sreelatha , Nokes, Brandon T , Pack, Allan I , Pien, Grace W , Piper, Amanda J , Ravesloot, Madeline J L , Redline, Susan , Rotenberg, Brian W , Sarmiento, Kathleen F , Schmickl, Christopher N , Shelgikar, Anita Valanju , Shochat, Isaac , Soose, Ryan J , Steele, Toby O , Stephens, Erika , Strohl, Kingman P , Suurna, Maria V , Vanderveken, Olivier M , Yu, Jason L , Rosen, Ilene M , Alt, Jeremiah A. , Barrera, Jose Enrique , Cabrera‐Muffly, Cristina , Chahine, Lana M. , Hoff, Paul T. , Ishman, Stacey L. , Jella, Tarun K. , Kapur, Vishesh K. , Kezirian, Eric J. , Krystal, Andrew D. , Lam, Derek J. , Malhotra, Atul , Mansukhani, Meghna P. , Mokhlesi, Babak , Pack, Allan I , Patil, Susheel P. , Sutherland, Kate

Mayo Clinic

International Forum of Allergy & Rhinology | September 7, 2022 | Volume: 13 | Issue: 7 | Pages: 1061-1482

10.1002/alr.23079 | PMID 36068685 Get It

ABSTRACT Background Evaluation and interpretation of the literature on obstructive sleep apnea (OSA) allows for consolidation and determination of the key factors important for clinical management of the adult OSA patient. Toward this goal, an international collaborative of multidisciplinary experts in sleep apnea evaluation and treatment have produced the International Consensus statement on Obstructive Sleep Apnea (ICS:OSA). Methods Using previously defined methodology, focal topics in OSA were assigned as literature review (LR), evidence‐based review (EBR), or evidence‐based review with recommendations (EBR‐R) formats. Each topic incorporated the available and relevant evidence which was summarized and graded on study quality. Each topic and section underwent iterative review and the ICS:OSA was created and reviewed by all authors for consensus. Results The ICS:OSA addresses OSA syndrome definitions, pathophysiology, epidemiology, risk factors for disease, screening methods, diagnostic testing types, multiple treatment modalities, and effects of OSA treatment on multiple OSA‐associated comorbidities. Specific focus on outcomes with positive airway pressure (PAP) and surgical treatments were evaluated. Conclusion This review of the literature consolidates the available knowledge and identifies the limitations of the current evidence on OSA. This effort aims to create a resource for OSA evidence‐based practice and identify future research needs. Knowledge gaps and research opportunities include improving the metrics of OSA disease, determining the optimal OSA screening paradigms, developing strategies for PAP adherence and longitudinal care, enhancing selection of PAP alternatives and surgery, understanding health risk outcomes, and translating evidence into individualized approaches to therapy.
Recent Hybrid Plasma Better Neutralizes Omicron Sublineages Than Old Hyperimmune Serum
Joyner, Michael J. , Joyner, Michael J , Focosi, Daniele , Casadevall, Arturo

Mayo Clinic

Clinical Infectious Diseases | September 6, 2022 | Volume: 76 | Issue: 3 | Pages: 554-554

10.1093/cid/ciac742 | PMID 36074894 Get It

Transcriptomic Analysis of Cirrhosis-Like Hepatocellular Carcinoma Reveals Distinct Molecular Characteristics and Pathologic Staging Implications
Treeck, Benjamin J. Van , Moreira, Roger K. , Mounajjed, Taofic, Ferrell, Linda D., Xue, Yue , Jessen, Erik , Davila, Jaime , Davila, Jaime I , Graham, Rondell P.

Mayo Clinic

American Journal of Clinical Pathology | September 6, 2022 | Volume: 158 | Issue: 6 | Pages: 750-758

10.1093/ajcp/aqac125 | PMID 36197918 Get It

Abstract Objectives Cirrhosis-like hepatocellular carcinoma (CL-HCC) is a rare hepatocellular malignancy characterized by multiple tumor nodules that clinically, radiologically, macroscopically, and microscopically mimic cirrhosis. We aimed to elucidate the molecular biology of CL-HCC and determine tumor nodule clonality. Methods We performed RNA sequencing on formalin-fixed, paraffin-embedded tissue from confirmed CL-HCC cases (n = 6), along with corresponding nonneoplastic hepatic tissue (n = 4) when available. Transcriptomes from our previous work on steatohepatitic hepatocellular carcinoma and The Cancer Genome Atlas (TCGA) were used for comparison purposes. Results Histologically, CL-HCC displayed innumerable nodules and extensive vascular invasion. Intratumoral nodule comparison indicated that the multiple nodules were all clonally related, not independent primaries. The unique histomorphologic appearance corresponded with a distinct transcriptome compared with other HCCs, including fibrolamellar HCC (n = 6), steatohepatitic HCC (n = 8), and conventional HCC in TCGA (n = 424). Tumor-normal gene expression analysis revealed consistent overexpression of several genes involved in degradation of tissue matrix. No recurrent translocations or point mutations were identified. CL-HCC showed a gene expression profile indicative of zone 2 hepatocytes. Conclusions CL-HCC’s distinctive clinicopathologic features correspond to a unique gene expression profile, increased expression of invasive markers, features of zone 2 hepatocytes, and features suggestive of intratumoral nodule monoclonality.
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)
Raghav, Kanwal , Ou, Fang‐Shu , Venook, Alan P. , Innocenti, Federico , Lenz, Heinz‐Josef , Kopetz, Scott , Lenz, Heinz-Josef , Kopetz, Scott , Venook, Alan P , Ou, Fang-Shu , Raghav, Kanwal P S , Sun, Ryan

Mayo Clinic

Journal of Clinical Oncology | September 6, 2022 | Volume: 41 | Issue: 3 | Pages: 472-478

10.1200/jco.22.00365 | PMID 36067452 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Acquired genomic alterations (Acq-GAs), specifically RAS, BRAF, and EGFR-ectodomain mutations and ERBB2 and MET amplifications, are recognized as major mechanisms of resistance to later-line anti–EGFR-antibody therapy in metastatic colorectal cancer (mCRC). However, data regarding emergence of these Acq-GAs under the selective pressure of first-line anti–EGFR-chemotherapy are lacking. We performed next-generation sequencing (Guardant360) on circulating tumor DNA obtained from paired plasma samples (pretreatment and postprogression) from the CALGB/SWOG-80405 trial, which randomly assigned patients with mCRC between first-line chemotherapy with cetuximab (anti–EGFR-chemotherapy) or bevacizumab (anti–VEGF-chemotherapy). The primary objective was to determine the prevalence of Acq-GAs on anti–EGFR-chemotherapy and compare this to the prevalence with anti–VEGF-chemotherapy on trial and pooled estimates (N = 292) seen with later-line anti–EGFR-antibody therapy as reported in the literature. Among the 61 patients on anti–EGFR-chemotherapy, only four (6.6%) developed ≥ 1 Acq-GAs of interest compared with 10.1% (7) on anti–VEGF-chemotherapy (odds ratio, 0.62; 95% CI, 0.20 to 2.11) and 62.0% on anti–EGFR-antibody therapy in later lines (odds ratio, 0.09; 95% CI, 0.03 to 0.23). Acq-GAs, classically associated with anti–EGFR-antibody resistance in later lines ( RAS, BRAF, and EGFR-ectodomain mutations; ERBB2 and MET amplifications), were rare with up-front use of anti–EGFR-chemotherapy indicating divergent resistance mechanisms. These findings have critical translational relevance to timing and value of circulating tumor DNA–guided anti-EGFR rechallenge in patients with mCRC, especially those treated with anti-EGFR therapy upfront.
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model
Sharma, Vidit , Wymer, Kevin , Khanna, Abhinav, Thompson, R. Houston, Costello, Brian A. , Leibovich, Bradley C. , Boorjian, Stephen A. , Moriarty, James, Borah, Bijan J. , Joyce, Daniel , Moriarty, James P.

Mayo Clinic

Journal of Urology | September 6, 2022 | Volume: 209 | Issue: 1 | Pages: 89-98

10.1097/ju.0000000000002953 | PMID 36067373 Get It

Second and Third Line Treatment Strategies in Multiple Myeloma: a Referral-Center Experience
Goldman‐Mazur, Sarah , Rajkumar, S. Vincent , Kapoor, Prashant , Lacy, Martha Q. , Gertz, Morie A. , Buadi, Francis K. , Hayman, Suzanne R. , Dingli, David , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Rajkumar, S Vincent , Gertz, Morie A , Buadi, Francis K , Dingli, David , Visram, Alissa , Dispenzieri, Angela , Gonsalves, Wilson I. , Muchtar, Eli , Leung, Nelson

Mayo Clinic

No container title available | September 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1995380/v1 Get It

Abstract The treatment landscape for relapsed multiple myeloma (MM) has increased. In this study we aimed to characterize 2nd (n = 1439) and 3rd (n = 1104) line regimens and compare the results between subgroups based on the year of treatment initiation (2nd line: 2003–2008, 2009–2015, 2016–2021; 3rd line: 2004–2009, 2010–2015, and 2016–2021). In both 2nd and 3rd line we observed increasing use of novel agents (from 78–95% and from 77–95%, respectively) and triplet regimens (from 15–69% and from 21–71%, respectively). Most frequently used regimens in the last studied periods included lenalidomide-dexamethasone (RD; 14%), carfilzomib-RD (12%) and daratumumab-RD (10%) for 2nd line, and daratumumab-pomalidomide-dexamethasone (11%) and daratumumab-RD (10%) for 3rd line. Median time to next treatment from 2nd line therapy has improved from 10.4 months (95% CI 8.4–12.4) to 16.6 months (95% CI 13.3–20.3; p < 0.001). The median overall survival from 1st relapse increased from 30.9 months (95% CI 26.8–183.0) to 65.8 months (95% CI 50.7–72.8; p < 0.001). Over the last two decades more patients were treated with newer agents and triplets for relapsed MM. The landscape of regimens has become more diverse, and the survival after 1st relapse is continually improving.
Prdx5 regulates DNA damage response through autophagy-dependent Sirt2-p53 axis
Agborbesong, Ewud , Zhou, Julie , Li, Linda X, Harris, Peter C. , Calvet, James P. , Zhou, Julie X., Li, Xiaogang , Harris, Peter C , Li, Xiaogang

Mayo Clinic

Human Molecular Genetics | September 6, 2022 | Volume: 32 | Issue: 4 | Pages: 567-579

10.1093/hmg/ddac218 | PMID 36067023 Get It

Abstract DNA damage response (DDR) is an important signaling-transduction network that promotes the repair of DNA lesions which can induce and/or support diseases. However, the mechanisms involved in its regulation are not fully understood. Recent studies suggest that the peroxiredoxin 5 (Prdx5) enzyme, which detoxifies reactive oxygen species, is associated to genomic instability and signal transduction. Its role in the regulation of DDR, however, is not well characterized. In this study, we demonstrate a role of Prdx5 in the regulation of the DDR signaling pathway. Knockdown of Prdx5 resulted in DNA damage manifested by the induction of phosphorylated histone H2AX (γ-H2AX) and p53-binding protein 1 (53BP1). We show that Prdx5 regulates DDR through (1) polo-like kinase 1 (Plk1) mediated phosphorylation of ataxia telangiectasia mutated (ATM) kinase to further trigger downstream mediators Chek1 and Chek2; (2) the increase of the acetylation of p53 at lysine 382, stabilizing p53 in the nucleus and enhancing transcription and (3) the induction of autophagy, which regulates the recycling of molecules involved in DDR. We identified Sirt2 as a novel deacetylase of p53 at lysine 382, and Sirt2 regulated the acetylation status of p53 at lysine 382 in a Prdx5-dependent manner. Furthermore, we found that exogenous expression of Prdx5 decreased DNA damage and the activation of ATM in Pkd1 mutant renal epithelial cells, suggesting that Prdx5 may play a protective role from DNA damage in cystic renal epithelial cells. This study identified a novel mechanism of Prdx5 in the regulation of DDR through the ATM/p53/Sirt2 signaling cascade.
A Clinical Audit of Cardiovascular Risk Factors and Disease in Patients with Rheumatoid Arthritis - SURF-RA
Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joseph, Crowson, Cynthia S. , Riel, Piet L. C. M. van , Rollefstad, Silvia , Graham, Ian D. , Semb, Anne Grete , Kerola, Anne M , Kitas, George D. , Graham, Ian

Mayo Clinic

Mediterranean Journal of Rheumatology | September 6, 2022 | Volume: 33 | Issue: 2 | Pages: 201

10.31138/mjr.33.2.201 | PMID 36128215 Get It

Characterization of National Medical Societies’ Accessible Resources to Support Underrepresented Minority and Female Trainees
Kandi, Lyndsay A. , Jarvis, Tyler L. , Movtchan, Nellie V., Teven, Chad M. , Rebecca, Alanna M. , Hammond, Jacob B.

Mayo Clinic

JAMA Network Open | September 6, 2022 | Volume: 5 | Issue: 9 | Pages: e2230243

10.1001/jamanetworkopen.2022.30243 | PMID 36066891 Get It

Abstract A13: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Guièze, Romain , Johnson, Connor, Tausch, Eugen , Lemvigh, Camilla K. , Messer, Conor, Levovitz, Chaya , Broséus, Julien , Li, Shuqiang , Lin, Ziao , Knisbacher, Binyamin A. , Schneider, Christof , Rassenti, Laura Z., Cymbalista, Florence, Livak, Kenneth J. , Brown, Jennifer R. , Paridi, Laxmi, Getz, Gaddy, Wu, Catherine J. , Parry, Erin M. , Leshchiner, Ignaty , Parikh, Sameer A. , Utro, Filippo , Rhrissorrakrai, Kahn , Davids, Matthew S. , Kipps, Thomas J. , Jain, Nitin , Wierda, William G. , Kay, Neil E. , Danysh, Brian P. , Stewart, Chip , Neuberg, Donna , Stilgenbauer, Stephan

Mayo Clinic

Blood Cancer Discovery | September 6, 2022 | Volume: 3 | Issue: 5_Supplement | Pages: A13-A13

10.1158/2643-3249.lymphoma22-a13 Get It

Abstract Richter syndrome (RS), an aggressive lymphoma that develops in patients with chronic lymphocytic leukemia (CLL), is a striking example of histologic transformation. While recent therapeutic advances have transformed the treatment landscape of CLL and lymphoma, RS remains associated with dismal overall survival. Despite an advanced genomic and molecular characterization of CLL over the past decade, the current understanding of the genetic factors driving evolution of CLL to RS is limited. To decipher the genetics underlying this transformation, we have performed an integrative analysis of exome, genome and transcriptome data generated from matched RS and CLL samples from a discovery cohort of 53 patients with newly diagnosed RS of DLBCL histology. Through computational deconvolution of CLL and RS clones, we constructed phylogenetic relationships and traced evolution of CLL to RS, confirming both clonal related (87%) and unrelated cases (13%). In addition to identifying recognized RS-risk genetic lesions, we discovered novel RS-specific alterations, including 5 putative somatic driver genes (IRF2BP2, SRSF1, B2M, DNMT3A and EZH2), frequent copy number alterations beyond del(9p21)(CDKN2A/B), (including amp(7q21.2) (CDK6), amp(9p24) (PDL1/L2), and amp(1q23)(MCL1)), and recurrent whole genome duplication and chromothripsis. Integration of exome and genome sequencing data led to the identification of distinct molecular subtypes of RS with prognostic importance. To confirm these molecular subtypes, a validation cohort of 47 RS cases has been assembled with paired exome and transcriptome data. To further investigate the stepwise clonal evolution of CLL to RS, we performed single-cell RNA-sequencing on biopsy samples obtained at diagnosis from 5 individuals with clonally related transformation. Using a novel tool, CNVSingle, we inferred allele specific single-cell copy number alterations that enabled identification of the single-cell clusters representing distinct CLL and RS genetic subclones as well as intermediate, or transitional, evolutionary states. RS cells displayed gene expression enriched in pathways of MYC targets and cell cycle, in line with similar analysis on bulk transcriptomes. Finally, by ultra-low pass (ULP)-WGS sequencing of plasma samples from RS patients, we demonstrate detection of RS tumor DNA in plasma months prior to initial clinical diagnosis (n=3 of 6) or post-allogeneic stem cell transplant relapse (n=2 of 2). cfDNA is thus a promising tool for early detection of emerging RS and RS relapse as well as for non-invasive detection surrounding diagnosis. Altogether, our study defines RS-specific alterations and provides a molecular definition of RS, identifies distinct genetic subtypes of RS with prognostic significance, traces the evolutionary path to RS and suggests future strategies for improved detection. Citation Format: Erin M Parry, Ignaty Leshchiner, Romain Guieze, Connor Johnson, Eugen Tausch, Sameer A Parikh, Camilla K Lemvigh, Conor Messer, Filippo Utro, Chaya Levovitz, Kahn Rhrissorrakrai, Matthew S Davids, Julien Broseus, Shuqiang Li, Ziao Lin, Binyamin A Knisbacher, Christof Schneider, Laura Z Rassenti, Thomas J Kipps, Nitin Jain, William Wierda, Florence Cymbalista, Neil E Kay, Kenneth J Livak, Brian P Danysh, Chip Stewart, Donna Neuberg, Jennifer R Brown, Laxmi Paridi, Stephan Stilgenbauer, Gaddy Getz, Catherine Wu. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome [abstract]. In: Proceedings of the Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2022 Jun 23-26; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2022;3(5_Suppl):Abstract nr A13.